[1]MIRABELLO L,TROISI RJ,SAVAGE SA.Osteosarcoma incidence and survival rates from 1973 to 2004:data from the surveillance,epidemiology,and end results Program [J].Cancer,2009,115(7):1531e43.
[2]SMELAND S,BIELACK SS,WHELAN J,et al.Survival and prognosis with osteosarcoma:outcomes in more than 2000 patients in the EURAMOS-1 (European and American Osteosarcoma Study) cohort [J].Eur J Cancer,2019,109:36-50.
[3]BARTEL DP.MicroRNAs:target recognition and regulatory functions [J].Cell,2009,136:215-233.
[4]WANG JC,LIU SZ,SHI JY,et al.The role of miRNA in the diagnosis,prognosis,and treatment of osteosarcoma [J].Cancer Biother Radiopharm,2019,34(10):605-613.
[5]JACKSON RJ,STANDART N.How do microRNAs regulate gene expression[J].Sci STKE,2007,2007(367):re1.
[6]ZHAO JZ,HU CX,CHI JD,et al.miR-24 promotes the proliferation,migration and invasion in human tongue squamous cell carcinoma by targeting FBXW7 [J].Oncol Rep,2016,36(2):1143-1149.
[7]ZHANG HY,DUAN JJ,QU YJ,et al.Onco-miR-24 regulates cell growth and apoptosis by targeting BCL2L11 in gastric cancer [J].Protein Cell,2016,7(2):141-151.
[8]LIU R,ZHANG HY,WANG X,et al.The miR-24-Bim pathway promotes tumor growth and angiogenesis in pancreatic carcinoma [J].Oncotarget,2015,6(41):43831-43842.
[9]YAN L,MA JZ,ZHU YP,et al.miR-24-3p promotes cell migration and proliferation in lung cancer by targeting SOX7 [J].J Cell Biochem,2018,119(5):3989-3998.
[10]JAFFE N.Osteosarcoma:review of the past,impact on the future.The American experience [J].Cancer Treat Res,2009,152:239-262.
[11]CALIN GA,DUMITRU CD,SHIMIZU M,et al.Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia [J].Proc Natl Acad Sci USA,2002,99:15524.
[12]FLEMMING A.Heart failure:Targeting miRNA pathology in heart disease [J].Nat Rev Drug Discov,2014,13:336.
[13]DI LEVA G,GAROFALO M,CROCE CM.MicroRNAs in cancer [J].Annu Rev Pathol,2014,9:287.
[14]NITURE S,GADI S,QI Q,et al.MicroRNA-483-5p inhibits hepatocellular carcinoma cell proliferation,cell steatosis,and fibrosis by targeting PPARα and TIMP2 [J].Cancers (Basel),2023,15(6):1715.
[15]JAVDANI H,MOLLAEI H,KARIMI F,et al.Review article epithelial to mesenchymal transition-associated microRNAs in breast cancer [J].Mol Biol Rep,2022,49(10):9963-9973.
[16]DONG ZH,LIAO ZP,He YL,et al.Advances in the biological functions and mechanisms of miRNAs in the development of osteosarcoma [J].Technol Cancer Res Treat,2022,21:15330338221117386.
[17]JAMAYRAN AK,OKSUZ BA,AFANASYEVA Y,et al.Prognostic role of elevated miR-24-3p in breast cancer and its association with the metastatic process [J].Oncotarget,2018,9(16):12868-12878.
[18]WANG B,YAN LF,SHI WH,et al.CircRNA PVT1 promotes proliferation and chemoresistance of osteosarcoma cells via the miR-24-3p/KLF8 axis [J].Int J Clin Oncol,2022,27(4):811-822.
[19]WOODS AL,HALL PA,SHEPHERD NA,et al.The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade,S+G2+M phase fraction (flow cytometric analysis) and prognosis [J].Histopathology,1991,19(1):21-27.